Affimed lands milestone from Roche; Puma touts new PHII data on cervical cancer

→ While Affimed $AFMD works to shake off the FDA hold on its Phase I program, the team is still making preclinical progress with its innate cell engager-based cancer therapies. The German biotech said its big partner at Genentech has issued an unspecified payment for a preclinical milestone — hopefully the first of many in a collaboration worth up to $5 billion.

Puma Biotechnology has posted positive data for neratininb from a PhII study involving HER2-mutated cervical cancer patients $PBYI. Out of 11 patients researchers counted “3 patients with confirmed partial responses and 3 patients with stable disease that lasted greater than 16 weeks. The median progression free survival was 7.0 months.”

→ Antibiotics developer Iterum Therapeutics $ITRM has collected four more qualified infectious disease product (QIDP) designations for sulopenem in the following indications: community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory disease. Designed to incentivize drug development in face of growing microbial resistance, QIDP grants drugs an additional five-year extension of exclusivity among other provisions. Iterum’s drug has previously earned the designation for three other indications, all currently tested in pivotal Phase III.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->